Angeles Investment Advisors LLC Reduces Stock Holdings in Danaher Co. (NYSE:DHR)

Angeles Investment Advisors LLC reduced its stake in shares of Danaher Co. (NYSE:DHR) by 7.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,202 shares of the conglomerate’s stock after selling 96 shares during the period. Angeles Investment Advisors LLC’s holdings in Danaher were worth $300,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of DHR. Cape Investment Advisory Inc. purchased a new stake in shares of Danaher during the 4th quarter valued at about $25,000. Tsfg LLC raised its holdings in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the 2nd quarter valued at about $25,000. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter worth approximately $25,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in Danaher during the 1st quarter worth approximately $30,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 in the last 90 days. 11.10% of the stock is currently owned by company insiders.

Danaher Trading Up 0.7 %

NYSE:DHR opened at $276.06 on Tuesday. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The firm has a market capitalization of $199.37 billion, a P/E ratio of 46.79, a P/E/G ratio of 4.48 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The business has a 50 day simple moving average of $265.25 and a 200 day simple moving average of $256.67.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm posted $2.05 EPS. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. Equities research analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on DHR shares. Barclays lifted their price objective on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Bank of America lifted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Evercore ISI dropped their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Finally, Robert W. Baird lifted their price objective on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.